These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 16098969)
21. Aberrant glycosylation of alpha-dystroglycan and congenital muscular dystrophies. Endo T Acta Myol; 2005 Oct; 24(2):64-9. PubMed ID: 16550917 [TBL] [Abstract][Full Text] [Related]
22. Characterization of the LARGE family of putative glycosyltransferases associated with dystroglycanopathies. Grewal PK; McLaughlan JM; Moore CJ; Browning CA; Hewitt JE Glycobiology; 2005 Oct; 15(10):912-23. PubMed ID: 15958417 [TBL] [Abstract][Full Text] [Related]
23. Perlecan is recruited by dystroglycan to nodes of Ranvier and binds the clustering molecule gliomedin. Colombelli C; Palmisano M; Eshed-Eisenbach Y; Zambroni D; Pavoni E; Ferri C; Saccucci S; Nicole S; Soininen R; McKee KK; Yurchenco PD; Peles E; Wrabetz L; Feltri ML J Cell Biol; 2015 Feb; 208(3):313-29. PubMed ID: 25646087 [TBL] [Abstract][Full Text] [Related]
24. Absence of post-phosphoryl modification in dystroglycanopathy mouse models and wild-type tissues expressing non-laminin binding form of α-dystroglycan. Kuga A; Kanagawa M; Sudo A; Chan YM; Tajiri M; Manya H; Kikkawa Y; Nomizu M; Kobayashi K; Endo T; Lu QL; Wada Y; Toda T J Biol Chem; 2012 Mar; 287(12):9560-7. PubMed ID: 22270369 [TBL] [Abstract][Full Text] [Related]
25. Muscle-specific expression of LARGE restores neuromuscular transmission deficits in dystrophic LARGE(myd) mice. Gumerson JD; Davis CS; Kabaeva ZT; Hayes JM; Brooks SV; Michele DE Hum Mol Genet; 2013 Feb; 22(4):757-68. PubMed ID: 23222475 [TBL] [Abstract][Full Text] [Related]
26. Defective glycosylation in muscular dystrophy. Muntoni F; Brockington M; Blake DJ; Torelli S; Brown SC Lancet; 2002 Nov; 360(9343):1419-21. PubMed ID: 12424008 [TBL] [Abstract][Full Text] [Related]
27. Perlecan and Dystroglycan act at the basal side of the Drosophila follicular epithelium to maintain epithelial organization. Schneider M; Khalil AA; Poulton J; Castillejo-Lopez C; Egger-Adam D; Wodarz A; Deng WM; Baumgartner S Development; 2006 Oct; 133(19):3805-15. PubMed ID: 16943280 [TBL] [Abstract][Full Text] [Related]
29. Disrupted mechanical stability of the dystrophin-glycoprotein complex causes severe muscular dystrophy in sarcospan transgenic mice. Peter AK; Miller G; Crosbie RH J Cell Sci; 2007 Mar; 120(Pt 6):996-1008. PubMed ID: 17311848 [TBL] [Abstract][Full Text] [Related]
30. Biochemical and biophysical changes underlie the mechanisms of basement membrane disruptions in a mouse model of dystroglycanopathy. Zhang P; Yang Y; Candiello J; Thorn TL; Gray N; Halfter WM; Hu H Matrix Biol; 2013 Apr; 32(3-4):196-207. PubMed ID: 23454088 [TBL] [Abstract][Full Text] [Related]
31. Profound skeletal muscle depletion of alpha-dystroglycan in Walker-Warburg syndrome. Jiménez-Mallebrera C; Torelli S; Brown SC; Feng L; Brockington M; Sewry CA; Beltrán-Valero De Bernabé D; Muntoni F Eur J Paediatr Neurol; 2003; 7(3):129-37. PubMed ID: 12788039 [TBL] [Abstract][Full Text] [Related]
32. The dystroglycan complex is necessary for stabilization of acetylcholine receptor clusters at neuromuscular junctions and formation of the synaptic basement membrane. Jacobson C; Côté PD; Rossi SG; Rotundo RL; Carbonetto S J Cell Biol; 2001 Feb; 152(3):435-50. PubMed ID: 11157973 [TBL] [Abstract][Full Text] [Related]
33. Investigating the functions of LARGE: lessons from mutant mice. Hewitt JE Methods Enzymol; 2010; 479():367-86. PubMed ID: 20816177 [TBL] [Abstract][Full Text] [Related]
34. A new patient-derived iPSC model for dystroglycanopathies validates a compound that increases glycosylation of α-dystroglycan. Kim J; Lana B; Torelli S; Ryan D; Catapano F; Ala P; Luft C; Stevens E; Konstantinidis E; Louzada S; Fu B; Paredes-Redondo A; Chan AE; Yang F; Stemple DL; Liu P; Ketteler R; Selwood DL; Muntoni F; Lin YY EMBO Rep; 2019 Nov; 20(11):e47967. PubMed ID: 31566294 [TBL] [Abstract][Full Text] [Related]
35. Loss of alpha-dystroglycan laminin binding in epithelium-derived cancers is caused by silencing of LARGE. de Bernabé DB; Inamori K; Yoshida-Moriguchi T; Weydert CJ; Harper HA; Willer T; Henry MD; Campbell KP J Biol Chem; 2009 Apr; 284(17):11279-84. PubMed ID: 19244252 [TBL] [Abstract][Full Text] [Related]
36. Tumor suppressor function of laminin-binding alpha-dystroglycan requires a distinct beta3-N-acetylglucosaminyltransferase. Bao X; Kobayashi M; Hatakeyama S; Angata K; Gullberg D; Nakayama J; Fukuda MN; Fukuda M Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12109-14. PubMed ID: 19587235 [TBL] [Abstract][Full Text] [Related]
37. Binding of the G domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins. Talts JF; Andac Z; Göhring W; Brancaccio A; Timpl R EMBO J; 1999 Feb; 18(4):863-70. PubMed ID: 10022829 [TBL] [Abstract][Full Text] [Related]
38. Pikachurin interaction with dystroglycan is diminished by defective O-mannosyl glycosylation in congenital muscular dystrophy models and rescued by LARGE overexpression. Hu H; Li J; Zhang Z; Yu M Neurosci Lett; 2011 Feb; 489(1):10-5. PubMed ID: 21129441 [TBL] [Abstract][Full Text] [Related]
39. Dystroglycan function requires xylosyl- and glucuronyltransferase activities of LARGE. Inamori K; Yoshida-Moriguchi T; Hara Y; Anderson ME; Yu L; Campbell KP Science; 2012 Jan; 335(6064):93-6. PubMed ID: 22223806 [TBL] [Abstract][Full Text] [Related]
40. Linker molecules between laminins and dystroglycan ameliorate laminin-alpha2-deficient muscular dystrophy at all disease stages. Meinen S; Barzaghi P; Lin S; Lochmüller H; Ruegg MA J Cell Biol; 2007 Mar; 176(7):979-93. PubMed ID: 17389231 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]